Introducing the Investigator Global Assessment of Hidradenitis Suppurativa (I-GLASS) instrument
British Journal of Dermatology · 19.05.2026 · 194 (6) · 1151-1153
DOI: 10.1093/bjd/ljag083 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 23.03.2026. Verfasst von John R Ingram und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infection & Immunity, Cardiff University, Cardiff, UK. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
To date, the primary endpoint of hidradenitis suppurativa (HS) clinical trials is typically a focused lesion count, which has been shown to be error prone and which may not comprehensively measure the inflammatory burden. Unlike lesions of other inflammatory skin diseases such as atopic dermatitis, vitiligo and alopecia areata, HS lesions exhibit substantial morphological heterogeneity. Accordingly, the Investigator Global Assessment of Hidradenitis Suppurativa (I-GLASS) instrument was developed.
Autor:innen und Institutionen
- Division of Infection & Immunity, Cardiff University, Cardiff, UK.
- Northwell Health, New Hyde Park, NY, USA.
ORCID-Profile: John R Ingram, Amit Garg
Zitieren
APA
Ingram, J. R., & Garg, A. (2026). Introducing the Investigator Global Assessment of Hidradenitis Suppurativa (I-GLASS) instrument. British Journal of Dermatology, 194(6), 1151-1153. https://doi.org/10.1093/bjd/ljag083
Vancouver
Ingram JR, Garg A. Introducing the Investigator Global Assessment of Hidradenitis Suppurativa (I-GLASS) instrument. British Journal of Dermatology. 2026;194(6):1151-1153. doi:10.1093/bjd/ljag083
BibTeX
@article{Ingram2026,
author = {Ingram, John R and Garg, Amit},
title = {Introducing the Investigator Global Assessment of Hidradenitis Suppurativa (I-GLASS) instrument},
journal = {British Journal of Dermatology},
year = {2026},
volume = {194},
number = {6},
pages = {1151--1153},
doi = {10.1093/bjd/ljag083}
}
EUVIMED